Microvascular Dysfunction in Obesity
NADPH Oxidase Activity and Muscle Microvascular Dysfunction in Obesity
1 other identifier
interventional
25
1 country
1
Brief Summary
Impaired endothelial function is observed in disease states related to obesity, such as atherosclerosis, coronary artery disease, and diabetes. Reactive oxygen species (ROS) production and resultant oxidative stress contribute to the development of these obesity-related diseases. The enzyme NADPH-oxidase is a major source of oxidative stress within the vasculature, and has been linked with the Metabolic Syndrome. In the investigator's previously funded studies, the investigators demonstrated for the first time that: 1) in vivo ROS were elevated in skeletal muscle of obese as compared to lean or overweight human subjects, 2) perfusion of the NADPH-oxidase inhibitor apocynin locally into muscle normalized ROS levels and reversed local microvascular endothelial dysfunction in the obese individuals, and 3) aerobic exercise training was effective at attenuating in vivo hydrogen peroxide production and reversing microvascular endothelial dysfunction in the obese individuals. The investigators will investigate in this R15 renewal application the mechanism of exercise training-induced alterations in ROS production and action on endothelial dysfunction in obesity using our newly developed microdialysis methodology of monitoring ROS production, in combination with analysis of muscle biopsy samples obtained before and after our previously tested 8-week intervention of aerobic interval exercise training. The objectives of this study are to determine the impact of in vivo NADPH oxidase activity on endothelial function in obese individuals, and to determine the mechanism of training-induced improvements in endothelial function. The investigator's unique microdialysis methodology will allow monitoring of microvascular/endothelial function and ROS generation, as well as the administration of pharmacological agents directly into muscle. The central hypothesis is that it is upregulation of both mitochondrial ROS and NADPH oxidase-derived ROS that results in endothelial dysfunction in obesity, and that exercise training down-regulates mitochondrial-derived ROS, and NADPH oxidase 4, thereby improving endothelial function. The aims of this proposal are to: 1) determine the contributions of mitochondrial ROS and specific NADPH oxidase isoforms to the NADPH oxidase dependent endothelial dysfunction in skeletal muscle of obese individuals; 2) determine the mechanism of ROS reduction and improved endothelial function resulting from an 8-week aerobic interval training program.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable obesity
Started Nov 2019
Longer than P75 for not_applicable obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2018
CompletedFirst Posted
Study publicly available on registry
September 12, 2019
CompletedStudy Start
First participant enrolled
November 20, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 19, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2027
December 11, 2025
December 1, 2025
7 years
August 9, 2018
December 5, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Reactive oxygen species (ROS)
reactive oxygen species as indicated by H2O2 concentration measured with microdialysis
change from week 0 to week 8
Secondary Outcomes (1)
Muscle blood flow
change from week 0 to week 8
Study Arms (1)
Exercise training
EXPERIMENTALEight weeks of interval exercise training
Interventions
Eligibility Criteria
You may qualify if:
- There will be no restrictions with regard to race, sex, or socioeconomic status.
- Women will be premenopausal
- Women will be on combined estrogen/progestin hormonal contraceptive therapy (oral pill, transdermal patch or vaginal ring).
- Sedentary obese individuals will have been weight stable for the preceding 6 months.
- Sedentary obese individuals will have the Metabolic Syndrome as defined according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
- Individuals with the Metabolic Syndrome will have at least three of the following:
- Central obesity as measured by waist circumference (men \>40 inches; women \>35 inches);
- Fasting blood triglycerides \> 150 mg/dL;
- Blood HDL cholesterol in men\<40 mg/dL and women \<50 mg/dL;
- Blood pressure \> 130/85 mmHg; 5) Fasting blood glucose \> 110 mg/dL, and (not per ATP III) a 2-hour GTT glucose of 140-200 mg/dl.
You may not qualify if:
- Subjects participating in purposeful endurance exercise training (\>20 min/day, \>1 day/week) will be excluded.
- Pre-menopausal female subjects must not be pregnant or lactating, and must have had regular menstrual cycles for the past year.
- Individuals taking medications that may affect central or peripheral circulation,
- Individuals on nonsteroidal anti-inflammatory agents or serotonin reuptake inhibitors,
- Individuals who smoke or chew tobacco,
- Individuals with diabetes (fasting blood glucose \>125 mg/dL),
- hypertension \>160/95 mmHg
- Individuals with congestive heart failure, angina, or peripheral vascular disease. --Individuals with ECG evidence of serious arrhythmias and/or acute myocardial ischemia reflected in ST-segment depression of 1 mm or greater at rest or during exercise.
- Individuals with chronic infections, paralysis due to stroke, advanced Parkinson's Disease, severe rheumatoid arthritis or other serious orthopedic problems that would prevent performance of the exercise training tasks will be excluded.
- Individuals taking antioxidant, herbal or vitamin supplementation for at least 2 weeks prior to investigation.
- Individuals ingesting caffeine the day of the experiment.
- Individuals whose weight changes by more than 5% during the training program.
- Individuals whose exercise adherence is below 90% of the exercise sessions or total exercise time.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Florida State University
Tallahassee, Florida, 32306, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert C Hickner, PhD
Florida State University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 9, 2018
First Posted
September 12, 2019
Study Start
November 20, 2019
Primary Completion (Estimated)
November 19, 2026
Study Completion (Estimated)
May 31, 2027
Last Updated
December 11, 2025
Record last verified: 2025-12